Results 171 to 180 of about 596,923 (316)

Exploring the Application Potential of α-Synuclein Molecular Probes in Early Diagnosis of Parkinson's Disease: Focus on Imaging Methods. [PDF]

ACS Chem Neurosci
Sun Q, Wu M, Xie R, Lai L, Chen Q, Guan J.   +5 more
europepmc   +1 more source

Identification and characterization of alternative sites and molecular probes for SARS-CoV-2 target proteins. [PDF]

Front Chem, 2022
Iyengar SM, Barnsley KK, Vu HY, Bongalonta IJA, Herrod AS, Scott JA, Ondrechen MJ.   +6 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Application of rare earth elements in dual-modality molecular probes. [PDF]

RSC Adv
He JF, Yang WW, Quan WX, Yang YC, Zhang Z, Luo QY.   +5 more
europepmc   +1 more source

Molecular probes for selective detection of cysteine cathepsins. [PDF]

Org Biomol Chem, 2021
Schleyer KA, Cui L.
europepmc   +1 more source

Developments of Molecular Probes for Detecting Biological Events Based on Polymeric Materials

, 2012
Kazuo Tanaka
openalex   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Recent advances in dual response molecular probes for biothiols. [PDF]

Smart Mol
Mwafulirwa M, Abdalla K, Bian W, Wei H, Xu L, Yu W, Hui Z, Yang Q, Sun X.   +8 more
europepmc   +1 more source

Bimodal Fluorescence/Magnetic Resonance Molecular Probes with Extended Spin Lifetimes. [PDF]

Chemistry, 2022
Yang S, Saul P, Mamone S, Kaltschnee L, Glöggler S.   +4 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source